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Abstract
Background: Management of thalassemia major requires patients to have life-long access to a
treatment regimen of regular blood transfusions coupled with iron chelation therapy. The objective
of this study was to investigate patients' reasons for missing iron chelation therapy with
desferrioxamine, and the support to sustain life-long adherence to treatment.
Methods: From October 1999 to May 2000 a survey of patients with thalassemia major was
conducted in ten countries: Cyprus, Egypt, Greece, Hong Kong, India, Iran, Italy, Jordan, Taiwan,
and the United States.
Results: 1,888 questionnaires (65%) were returned. Most patients (1,573) used desferrioxamine,
and 79% administered a dose at least 4 days a week. Inaccessibility of the drug was a common
reason for missing a dose in India (51%), and in Iran (25%), whereas, in any other country, it was a
reason for less than 17% of patients. Overall, 58% reported reasons for missing a dose related to
their beliefs or feelings about the medication, and 42% drug-related side effects.
Conclusion: Many patients miss doses of desferrioxamine and an opportunity remains to develop
interventions that provide more support to sustain use of desferrioxamine.
Background
Management of thalassemia major requires patients to
have life-long access to a treatment regimen of regular
blood transfusions coupled with iron chelation therapy
[1,2]. Adequate chelation can be achieved by regular use
of desferrioxamine infusions, which has been shown to be
critical for long-term disease-free survival – reducing the
risk of both iron overload and the associated life threaten-
ing complications [3,4]. Generally, regular blood transfu-
sions and iron chelation treatment with desferrioxamine
are initiated early in life; therefore, the patients and their
families have to sustain regular treatment throughout
their childhood, adolescent, and adult years.
Many patients and their families find it difficult to sustain
compliance with chronic treatment regimens for other life
Published: 23 April 2002
BMC Clinical Pharmacology 2002, 2:3
Received: 25 January 2002
Accepted: 23 April 2002
This article is available from: http://www.biomedcentral.com/1472-6904/2/3
© 2002 Ward et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided 
this notice is preserved along with the article's original URL.Page 1 of 9
(page number not for citation purposes)
BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/3threatening diseases that arise during childhood or ado-
lescence, such as bone marrow or renal transplantations
[5–7]. Patients receiving regular blood transfusions but
administering less than two-thirds of the recommended
desferrioxamine dose are known to increase their risk of
developing complications later in life as a result of accu-
mulating iron [8,9]. Consequently, a commitment to life-
long adherence to regular administration of desferrioxam-
ine is key to the long-term health of patients. To date re-
search into alternative iron chelators has resulted in the
marketing of one alternative agent, deferiprone. Desferri-
oxamine remains the mainstay of treatment, however, as
there are concerns about the relative long-term efficacy
and safety of deferiprone [10].
This survey was designed to collect data on the current
patterns of desferrioxamine use by patients in ten coun-
tries: Cyprus, Egypt, Greece, Hong Kong, India, Iran, Italy,
Jordan, Taiwan, and the United States. Patients were asked
about the frequency of administration of desferrioxamine
each week and their reasons for missing doses. In addi-
tion, this survey provided information about the support
currently available to patients and their families to contin-
ue with this life saving, but complex, treatment regimen.
Methods
Questionnaires
Questionnaires were developed in collaboration with ex-
perts in the treatment of thalassemia and specifically de-
signed to be self-administered by patients or, for children
younger than 14 years old, by their caregivers. The ques-
tionnaires were distributed and returned by mail. The
questionnaire distributed in India and the US was in Eng-
lish. For the remaining countries, it was translated by na-
tive speakers into Greek, Italian, Arabic, Farsi, or Chinese,
as appropriate. The initial translations were back translat-
ed and corrections made accordingly. In the pilot study,
translated questionnaires were completed by patients or
their caregivers and their feedback was used to improve
the design of the final questionnaire.
Data Collection
The survey was conducted in ten countries: Cyprus (CY),
Egypt (EG), Greece (GR), Hong Kong (HK), India (IN),
Iran (IR), Italy (IT), Jordan (JO), Taiwan (TA), and the
United States (US). In each country, the Thalassemia In-
ternational Federation (TIF) coordinators had access to
the local patient organization membership lists. The coor-
dinators randomly selected patients from these lists and
distributed to them a copy of the patient and caregiver
questionnaires. To ensure that the patients were randomly
selected from the membership, the coordinators divided
the total number of current members by the number of
questionnaires, and then selected patients from their list
at this interval. Patients or caregivers were asked to return
the completed questionnaires to the coordinators by mail
in the envelope provided (local postage was prepaid).
Each questionnaire had a unique identifier code but did
not include a patient's name; consequently, all the re-
sponses were anonymous. No letters were sent to ask the
non-responders to complete the questionnaire and no re-
muneration was extended to participants for returning the
questionnaire to the TIF coordinators.
Three hundred questionnaires were dispatched to each
country between October 1999 and January 2000, except
in Greece where two hundred were distributed. All re-
sponses returned by May 31, 2000 were translated, where
necessary, and all patients prescribed desferrioxamine
were included in these analyses (Table 1).
Table 1: Response rates by country and proportions of the patients prescribed desferrioxamine from each country
Country CY EG GR HK IN IR IT JO TA US Total
Membership 636 2,801 922 334 823 6,810 840 360 302 310 14,138
Questionnaires dis-
patched
300 300 200 300 300 300 300 300 300 300 2,900
Questionnaires com-
pleted
275 199 118 159 235 215 147 232 231 77 1,888
Response rate (%) 92 66 59 53 78 72 49 77 77 26 65
Desferrioxamine use, N 
(%)
267 (97) 120 (60) 112 (95) 147 (93) 128 (55) 200 (93) 132 (90) 185 (80) 212 (92) 70 (91) 1573 (83)
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tion about the frequency of missed doses, taking a higher
or lower dose of desferrioxamine than was prescribed dur-
ing the preceding month, and the sources of help to con-
tinue taking the drug regularly (i.e., doctor, health care
providers, family, friends, other patients, thalassemia as-
sociation or other sources). In addition the patients' rea-
sons for missing doses were investigated under five
categories: (1) access to desferrioxamine, (2) related to ad-
verse effects of desferrioxamine, (3) patient's beliefs and
feelings about the treatment, (4) inadequate support to
continue with the treatment, and (5) other reasons not
listed on the questionnaire. The responses classified as is-
sues related to access to desferrioxamine were those indi-
cating that it was not available or too expensive.
Responses indicating the reason for missing a dose was
due to side effects or that the infusions were very uncom-
fortable were grouped as related to adverse effects of des-
ferrioxamine. The questions pertaining to the patient's
beliefs and feelings included the daily use of an infusion,
taking too many medications, not believing treatment was
necessary, using natural remedies, feeling healthy, making
the patient feel different from their friends, and not liking
to medicate in front of people. The questions relating to
adequate support to continue taking desferrioxamine
asked the patients whether doses were missed because
health care providers, family, or friends did not seem to be
concerned about the patient's treatment.
Analyses
The data collected from the questionnaires are summa-
rized by reporting the proportions of patients answering
each item or, when appropriate, the mean and standard
deviation (SD). The analyses pool the responses from pa-
tients or caregivers, as questions were common to both
questionnaires.
Analyses included the patient characteristics and details of
the desferrioxamine treatment. The proportion of patients
in each age group, males, patients with each type of iron
related complication; as well as the mean age at diagnosis
and first blood transfusion are reported. The details of the
desferrioxamine treatment include mean age when first
used and current dose, frequency, and method of admin-
istration. The analyses also determined the proportion
missing at least one dose of desferrioxamine in the preced-
ing month, as well as the sources of help for adherence to
the prescribed regimen.
Comparisons were made using the chi square of the pro-
portions missing at least one dose of desferrioxamine in
the preceding month among: countries, age groups, pa-
tients with iron related complications, frequency of blood
transfusions, and method and frequency of desferrioxam-
ine administration. The odds of missing at least one dose
were determined using logistic regression to adjust for
both age and country. The following potential predictors
were also investigated: gender, age when desferrioxamine
was first used, frequency of administration per week, use
of a pump, and presence of iron-related complications.
Results
There were 1,888 respondents (65%) out of 2,900 ques-
tionnaires sent (Table 1), and 1,573 indicated they used
desferrioxamine. The demographic and clinical character-
istics of the patients using desferrioxamine are summa-
rized in Table 2. About half the respondents using
desferrioxamine were over 18 years old. Over 90% of the
patients responding to this survey in each country report-
ed that blood transfusions are received at intervals of 2 to
6 weeks. Typically, they were diagnosed with thalassemia
major before they were two years old, and started desferri-
oxamine treatment around the age of 6 years (Table 3).
Amongst the 1,573 patients prescribed desferrioxamine,
47% (n = 665) missed at least one dose during the preced-
ing month; the mean number of doses missed was 4.7 (SD
6.1). In addition, 23% (n = 335) indicated they took a
lower dose at least once in the preceding month; the mean
number of times a lower dose was taken was 3.9 (SD 4.7).
Far fewer reported taking a higher dose (10%, n = 144)
and the mean number of times a higher dose was taken
was 5.4 (SD 7.2).
Desferrioxamine was administered at least five days per
week by the majority of patients (62%, n = 941) (Table 3),
and four or more days a week by most patients (79%, n =
1187). The proportion of patients administering desferri-
oxamine four or more days per week varied significantly
among countries (chi square 163.5, p-value = 0.001). No
Table 2: Characteristics of respondents using desferrioxamine
31. Characteristics Respondents using desferri-





Male N (%) 765 (49.0)
Receiving blood transfusions N (%) 1564 (99.6)
Complications N (%)
Heart disease 154 (11.2)
Liver disease 258 (18.8)
Diabetes 133 (9.7)
Thyroid problem 85 (6.3)
32. Mean age at diagnosis, months
(SD)
19.1 (28.4)Page 3 of 9
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more each week in Egypt, India, and Iran (Figure 1), com-
pared to at least 76% in other countries.
The proportion of patients that missed at least one dose
also varied significantly among countries (Figure 2), (Chi
square 159.8, p-value = 0.001). Hong Kong and Taiwan
were the two countries with the highest risk of non-adher-
ence and Cyprus the lowest. Amongst patients younger
than 10 years old 19% missed at least one dose, age 10 to
18 years 33% and 48% of those older than 18 years. The
patients younger than 10 years old had a significantly low-
er risk of missing the prescribed dose compared to the old-
er age groups (Chi square 6.0, p = 0.05, df 2). Multivariate
analyses using logistic regression to adjust for country and
age revealed that both were significant predictors of the
odds of missing at least one dose (Table 4). However, gen-
der, age when desferrioxamine was first used, frequency of
administration per week, use of a pump, and presence of
iron-related complications were not associated with a sig-
nificantly increased risk of missing a dose.
The most frequently reported category of reasons for pa-
tients missing a dose was related to their beliefs and feel-
ings about the treatment (58%, n = 387) (Figure 3). The
next most frequent reason was the adverse effects of infus-
ing desferrioxamine (42%, n = 277). Problems accessing
the drug (13%, n = 86), or feeling a lack of support from
family, friends, or professional caregivers (5%, n = 35)
were infrequent reasons (Figure 3). While access to the
drug was the most common concern in India (51%, n =
26) and a frequent issue in Iran (25%, n = 15), it was a rea-
son given for missing a desferrioxamine dose for less than
17% of the patients in any other country. Many patients
(27%, n = 179) also indicated there were other reasons for
missing a dose that were not covered by the list in the
questionnaire.
Family or friends (77%, n = 951) and physicians (60%, n
= 660) were the most frequent sources of support for the
patients to continue administering desferrioxamine (Fig-
ure 4). Further, the most helpful source of support identi-
fied by the patients was their family and friends (53%, n
= 529) or their physicians (24%, n = 241). Other profes-
sionals and organizations were not frequently providing
help to these patients in any of the countries.
Discussion
Evidence that the prognosis for patients diagnosed with
thalassemia major is improved by regular blood transfu-
sions and iron chelation has been available for more than
25 years [11,12]. Over 90% of the patients responding to
this survey in each country reported that blood transfu-
sions are received at regular intervals, and most respond-
ents were infusing desferrioxamine at least four days per
week. In Egypt, India, and Iran, however, nearly half of pa-
tients were using desferrioxamine three days or less each
week and, from these responses, adequate access to desfer-
rioxamine is still a common reason for missing a dose in
Table 3: Desferrioxamine administration and proportions missing at least one dose in the preceding month
33. Characteristics Overall (N = 1573) Desferrioxamine use last month
Missed at least one dose (N = 665) No doses missed (N = 761)
Mean age first used years (SD) 6.3 (5.3) 6.6 (5.3) 6.0 (5.5)
>= 5 days per week, N (%) 941 (62.3) 397 (61.9) 470 (64.0)
Administered by pump, N (%) 1189 (81.6) 472 (76.9) 622 (85.8)
Mean daily dose (SD), g 1.7 (0.9) 1.7 (0.9) 1.7 (0.9)
Table 4: Adjusted Odds Ratios (95% Confidence Intervals) for the 
association between age and country with missing at least one 
dose in the past month
Variable Odds Ratio (95% CI) P-value
Age group vs 18+years
< 10 years 0.77 (0.93, 0.63) 0.01
10–18 years 1.19 (1.42, 1.00) 0.05
Country vs USA
Cyprus 0.32 (0.43, 0.23) <0001
Egypt 1.51 (2.24, 0.99) 0.04
Greece 1.18 (4.98, 3.56) 0.39
Hong Kong 3.05 (4.40, 0.47 <0001
India 0.95 (1.38, 1.52) 0.79
Iran 0.49 (0.67, 2.81) <0001
Italy 0.80 (1.13, 1.77) 0.20
Jordan 0.94 (1.30, 1.47) 0.71
Taiwan 2.54 (3.45, 0.54) <0001Page 4 of 9
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for renewed efforts to create awareness within public
health departments of this situation. It also provides addi-
tional data to support the local initiatives by patient or-
ganizations, as well as TIF, to ensure all patients gain
access to an effective chelation regimen.
Regular blood transfusions with inadequate iron chela-
tion therapy will not have immediate consequences for
the patients, but will inevitably increase their risk of devel-
oping iron overload complications later in life [8,13]. Our
study has shown that, overall, almost half of the patients
had missed one or more doses in the preceding month
and, on average a quarter were administering desferriox-
amine three days or less each week. In our survey, children
under ten years of age had a lower risk of missing a dose
than the older age groups. This is consistent with other ev-
idence that adolescents are generally less compliant than
younger children [7,14]. Relatively few studies have been
published on adherence to desferrioxamine, and different
methodologies, countries, and age groups make direct
comparisons between any studies of adherence inherently
difficult. Three small studies of patients with thalassemia
major found poor compliance with treatments, indicating
patients administer as little as 54% of the prescribed des-
ferrioxamine and, in one study, 23% of patients were tak-
ing less than 60% of the recommended dose [15–17]. In
the UK, recent estimates suggest that only about half the
patients are able to fully adhere to current iron chelation
treatments and when compared to adherent patients the
less adherent patients gain, on average, only ten years of
life [18].
Our findings are consistent with studies of adherence to
other chronic regimens for life threatening diseases that
arise during childhood or adolescence [5–7,19,20]. For
example, at least half of children receiving bone marrow
transplants had significant problems with adherence to a
long-term preventive antibiotic regimen [6]. Adults also
have problems adhering to chronic preventive regimens
Figure 1
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tension, for example, only 78% of patients persist with
treatment for one year [21].
The physician and the family were the most frequent
sources of support to continue administering desferriox-
amine. Adherence has been related to young people's psy-
chological adjustment to living with thalassemia and its
treatment [15,22–24]. From our survey, the limited
number of patients receiving support from local organiza-
tions suggests that there may be an opportunity to further
expand their role. For example, these organizations could
provide additional support groups where patients and
parents can share their experiences, learn that they are not
alone, and support each other. Such an approach has been
found to be well received [25].
The reasons given by patients for missing desferrioxamine
doses should be taken into account in developing inter-
ventions to enhance adherence. The most common rea-
sons for missing a dose were those related to the patients'
beliefs and feelings, rather than barriers to access the drug.
This finding is in accord with other research on adherence.
The most widely held theory is the "health belief model",
according to which patients' perceived susceptibility to
the illness or condition, its perceived severity, and per-
ceived benefits and barriers to compliance are the most
important factors determining their actions [26]. Another
approach gaining currency is based on behavior change
theory [27]. The results from our study indicate that inter-
ventions that increase adherence to chelation therapy
should be pursued [28]. The reasons must be investigated
further, however, given that at least a quarter of respond-
ents indicated there were reasons for missing a dose that
were not covered by the list included in the questionnaire.
One important limitation of this survey is that the re-
spondents were all members of a patient organization and
may therefore not be fully representative of patients with
thalassemia. It is possible that those who seek member-
ship are more involved in their illness and may thus re-
flect a greater commitment to treatment. Despite the good
Figure 2
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vary widely between countries. As responses were not
linked with medical records, the data remain self-reports.
Despite this limitation, we believe these data have value,
especially regarding the patients' reasons for non-compli-
ance and sources of support.
There were differences among countries in the ages of re-
spondents. For example, in Cyprus, Greece, Italy, and the
US, the majority of patients were adults, whereas in Egypt
and Jordan, patients younger than 10 years old formed the
largest age group. These differences may be a reflection of
variations in TIF membership, of public health policies
such as genetic screening, as well as of the impact of the
type of treatment previously provided in each country. For
example, during the last 30 years Cyprus, Greece, Italy,
and the US introduced carrier and prenatal screening pro-
grams and the birth of affected children has decreased
[10,29,30].
Conclusions
Adoption of life long adherence to regular administration
of desferrioxamine is clearly very important for the long-
term health of patients diagnosed with thalassemia major.
There remains an opportunity to improve life-long use of
desferrioxamine. Additional research to develop interven-
tions to support adherence to this vital, treatment is there-
fore essential, until alternative oral chelation agents are
developed.
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